How High Will Bloom Energy Stock Go?
Bloom Energy (NYSE:BE) has seen its shares surge by more…
Buy
64
VRNA Quote, Financials, Valuation and Earnings
Last price:
$68.56
Seasonality move
:
55.46%
Day range:
$66.97 - $69.10
52-week range:
$11.39 - $74.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
25.39x
Volume:
751.5K
Avg. volume:
1.6M
1-year change:
384.44%
Market cap:
$5.8B
Revenue:
$42.3M
EPS (TTM):
-$2.00
Analysts' Opinion
-
Consensus RatingVerona Pharma PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $94.10, Verona Pharma PLC has an estimated upside of 39.26% from its current price of $67.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $76.00 representing -12.48% downside risk from its current price of $67.24.
Fair Value
-
According to the consensus of 7 analysts, Verona Pharma PLC has 39.26% upside to fair value with a price target of $94.10 per share.
VRNA vs. S&P 500
-
Over the past 5 trading days, Verona Pharma PLC has underperformed the S&P 500 by -7.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Verona Pharma PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Verona Pharma PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Verona Pharma PLC reported revenues of $76.3M.
Earnings Growth
-
Verona Pharma PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Verona Pharma PLC reported earnings per share of -$0.16.
Enterprise value:
5.6B
EV / Invested capital:
11.94x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.23x
EV / Free cash flow:
-46.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-38.92%
Net Income Margin (TTM):
--
Return On Equity:
-85.84%
Return On Invested Capital:
-51.07%
Operating Margin:
-13.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $76.3M | |
| Gross Profit | -- | -- | -- | -- | $72.8M | |
| Operating Income | -$62.2M | -$73.2M | -$134.7M | -$26.6M | -$10.3M | |
| EBITDA | -$58.9M | -$58.2M | -$121.4M | -$23.2M | -$6.1M | |
| Diluted EPS | -$0.88 | -$0.80 | -$2.00 | -$0.32 | -$0.16 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $188.6M | $153M | $306.9M | $271.8M | $501M | |
| Total Assets | $190.2M | $169.3M | $323.1M | $289.9M | $525.9M | |
| Current Liabilities | $12.7M | $37.9M | $26.5M | $14.8M | $56.5M | |
| Total Liabilities | $17.7M | $43M | $46.4M | $64.9M | $299.3M | |
| Total Equity | $172.4M | $126.3M | $276.7M | $225M | $226.6M | |
| Total Debt | -- | $4.9M | $19.8M | $48.5M | $241.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.1M | -$58.1M | -$120.2M | -$13.6M | -$11.6M | |
| Cash From Investing | -$29K | -$16K | -$1.1M | -$16K | -$535K | |
| Cash From Financing | $210.2M | $21.1M | $267.4M | -$3.1M | $13.5M | |
| Free Cash Flow | -$51.2M | -$58.1M | -$121.3M | -$13.6M | -$12.1M | |
VRNA
Sector
Market Cap
$5.8B
$34.6M
Price % of 52-Week High
91.09%
43.69%
Dividend Yield
0%
0%
Shareholder Yield
-2.99%
-0.59%
1-Year Price Total Return
386.82%
-41.18%
Beta (5-Year)
0.206
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$67.92
200-day SMA
Buy
Level
$45.26
Bollinger Bands (100)
Buy
Level
50.68 - 67.46
Chaikin Money Flow
Sell
Level
-38.1M
20-day SMA
Buy
Level
$66.77
Relative Strength Index (RSI14)
Buy
Level
53.22
ADX Line
Sell
Level
21.16
Williams %R
Neutral
Level
-48.3191
50-day SMA
Buy
Level
$64.00
MACD (12, 26)
Buy
Level
1.52
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
220.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.241)
Sell
CA Score
(Annual)
Level (-1.6643)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.9418)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Stock Forecast FAQ
In the current month, VRNA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VRNA average analyst price target in the past 3 months is $94.10.
-
Where Will Verona Pharma PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Verona Pharma PLC share price will rise to $94.10 per share over the next 12 months.
-
What Do Analysts Say About Verona Pharma PLC?
Analysts are divided on their view about Verona Pharma PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Verona Pharma PLC is a Sell and believe this share price will drop from its current level to $76.00.
-
What Is Verona Pharma PLC's Price Target?
The price target for Verona Pharma PLC over the next 1-year time period is forecast to be $94.10 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VRNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Verona Pharma PLC is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VRNA?
You can purchase shares of Verona Pharma PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Verona Pharma PLC shares.
-
What Is The Verona Pharma PLC Share Price Today?
Verona Pharma PLC was last trading at $68.56 per share. This represents the most recent stock quote for Verona Pharma PLC. Yesterday, Verona Pharma PLC closed at $67.24 per share.
-
How To Buy Verona Pharma PLC Stock Online?
In order to purchase Verona Pharma PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Acuity a Good Stock to Buy Now?
Acuity Brands (NYSE:AYI) is an industrial company specializing in lighting.…
What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
74
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
71
NUTX alert for May 15
Nutex Health [NUTX] is up 8.24% over the past day.
Buy
81
EXEL alert for May 15
Exelixis [EXEL] is up 4.48% over the past day.
Sell
29
GLBE alert for May 15
Global E Online [GLBE] is down 4.2% over the past day.
